Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization

Expert Opin Drug Saf. 2021 Jul 6. doi: 10.1080/14740338.2021.1952979. Online ahead of print.ABSTRACTINTRODUCTION: Anti-angiogenesis therapy with intravitreal anti-VEGF agents is now the standard-of-care treatment for myopic choroidal neovascularization (CNV).AREAS COVERED: We provide a critical review of the safety of all the anti-VEGF agents currently used for treating myopic CNV including ranibizumab, aflibercept, conbercept, bevacizumab and ziv-aflibercept.EXPERT OPINION: Anti-VEGF therapy for myopic CNV with the currently available anti-VEGF drugs generally have favorable safety outcomes in the short-term. Nonetheless, ocular adverse events following anti-VEGF therapy for myopic CNV may develop and these include worsening or new development of myopic traction maculopathy, increased risk of retinal detachment and progression of chorioretinal atrophy. Clinicians should be aware of these potential complications and evaluate them before and after anti-VEGF therapy.PMID:34228553 | DOI:10.1080/14740338.2021.1952979

Source: Expert Opinion on Drug Safety - July 6, 2021 Category: Drugs & Pharmacology Authors: Danny S C Ng Mary Ho Lawrence P L Iu Timothy Y Y Lai Source Type: research